Axumin ® (fluciclovine F 18 injection) is an FDA-approved molecular imaging agent for use in positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on ...
BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, ...
The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...
- NCCN Guidelines aim to improve quality, effectiveness and efficiency of cancer care - Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that Axumin (fluciclovine F 18) ...
BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, ...
Axumin PET imaging has informed healthcare decisions for more than 125,000 men with recurrent prostate cancer across the United States, where it is available at 1,300 imaging centers and widely ...
BURLINGTON, Mass. & OXFORD, United Kingdom--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET ...
Comments on this technology were invited from clinical experts working in the field. The comments received are individual opinions and do not represent NICE's view. Two out of 6 specialist ...
Axumin® (fluciclovine F 18) injection is a novel product indicated for use in positron emission tomography (PET) imaging to identify suspected sites of prostate cancer recurrence in men.
Bracco and Blue Earth Diagnostics Ltd, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, welcomes proposed changes announced on ...
A phase 3 study from molecular imaging firm Blue Earth Diagnostics found that its Axumin contrast agent for PET scans could assist in the diagnosis of patients with glioma. Axumin, consisting of the ...
Axumin (Blue Earth Diagnostics Ltd) is a molecular imaging agent. It is intended for use in positron emission tomography (PET) to detect whether prostate cancer has returned in people whose blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results